{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:54:49Z","timestamp":1781549689670,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The receptor tyrosine kinase EphB4 is frequently overexpressed in epithelial cancers, including prostate cancer (PCa). SUMOylation is a post-translational modification that influences protein interactions, localisation and stability. This study investigated how SUMOylation regulates EphB4 localisation, stability and function in PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>EphB4 SUMOylation was analysed in PCa cell lines and its contribution to stability assessed using siRNA or chemical inhibition of SUMOylation. An EphB4 mutant protein (K616R) was expressed in PCa cells and proteasomal inhibition was used to assess its stability. Cell migration was measured using a scratch wound assay. Immunoprecipitation was used to determine if mutant EphB4 could be SUMOylated on other residues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>EphB4 in PCa cells is constitutively modified by SUMO2\/3 and acquires SUMO1 modification when stimulated with ephrin-B2 ligand. SUMOylation of K616 is critical for EphB4 stability. K616R EphB4 protein is degraded by the proteasome, and this is associated with reduced MYC protein and slower migration. Immunoprecipitation revealed that additional SUMOylated lysines may also contribute to EphB4 function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SUMOylation at K616 stabilises EphB4, promotes MYC signalling and PCa cell migration. These findings identify a novel mechanism regulating EphB4 and highlight SUMOylation as a potential target in EphB4-driven cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03442-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:34:29Z","timestamp":1776256469000},"page":"48-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SUMOylation of EphB4 enhances its stability in prostate cancer"],"prefix":"10.1038","volume":"135","author":[{"given":"Mohanan Sada Nand","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Mertens-Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Lisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Herington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Meutermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3227-2476","authenticated-orcid":false,"given":"Sally-Anne","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"3442_CR1","doi-asserted-by":"publisher","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.","journal-title":"Front Public Health"},{"key":"3442_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.tibs.2024.10.002","volume":"49","author":"EB Pasquale","year":"2024","unstructured":"Pasquale EB. Eph receptor signalling complexes in the plasma membrane. Trends Biochem Sci. 2024;49:1079\u201396.","journal-title":"Trends Biochem Sci"},{"key":"3442_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/cancers13020206","volume":"13","author":"M Anderton","year":"2021","unstructured":"Anderton M, van der Meulen E, Blumenthal MJ, Sch\u00e4fer G. The role of the Eph receptor family in tumourigenesis. Cancers. 2021;13:206.","journal-title":"Cancers"},{"key":"3442_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/ncb2122","volume":"12","author":"JW Astin","year":"2010","unstructured":"Astin JW, Batson J, Kadir S, Charlet J, Persad RA, Gillatt D, et al. Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat Cell Biol. 2010;12:1194\u2013204.","journal-title":"Nat Cell Biol"},{"key":"3442_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.semcancer.2017.10.002","volume":"56","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zhang H, Zhang Y. Targeting receptor tyrosine kinase EphB4 in cancer therapy. Semin Cancer Biol. 2019;56:37\u201346.","journal-title":"Semin Cancer Biol"},{"key":"3442_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-119","volume":"5","author":"YC Lee","year":"2005","unstructured":"Lee YC, Perren JR, Douglas EL, Raynor MP, Bartley MA, Bardy PG, et al. Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer. 2005;5:119.","journal-title":"BMC Cancer"},{"key":"3442_CR7","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1158\/0008-5472.CAN-04-2667","volume":"65","author":"G Xia","year":"2005","unstructured":"Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623\u201332.","journal-title":"Cancer Res"},{"key":"3442_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2042-y","volume":"10","author":"V Sagar","year":"2019","unstructured":"Sagar V, Vatapalli R, Lysy B, Pamarthy S, Anker JF, Rodriguez Y, et al. EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death Dis. 2019;10:801.","journal-title":"Cell Death Dis"},{"key":"3442_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41416-025-02942-5","volume":"132","author":"G Li","year":"2025","unstructured":"Li G, Ma B, Zhang S, Liu R, Siddiqi I, Sali A, et al. EphB4-ephrin-B2 are targets in castration-resistant prostate cancer. Br J Cancer. 2025;132:679\u201389.","journal-title":"Br J Cancer"},{"key":"3442_CR10","doi-asserted-by":"publisher","first-page":"E614","DOI":"10.1002\/ijc.27392","volume":"131","author":"R Rutkowski","year":"2012","unstructured":"Rutkowski R, Mertens-Walker I, Lisle JE, Herington AC, Stephenson SA. Evidence for a dual function of EphB4 as tumour promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand. Int J Cancer. 2012;131:E614\u201324.","journal-title":"Int J Cancer"},{"key":"3442_CR11","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1126\/science.adg5314","volume":"382","author":"X Shi","year":"2023","unstructured":"Shi X, Lingerak R, Herting CJ, Ge Y, Kim S, Toth P, et al. Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly. Science. 2023;382:1042\u201350.","journal-title":"Science"},{"key":"3442_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1083\/jcb.201305037","volume":"204","author":"A Schaupp","year":"2014","unstructured":"Schaupp A, Sabet O, Dudanova I, Ponserre M, Bastiaens P, Klein R. The composition of EphB2 clusters determines the strength in the cellular repulsion response. J Cell Biol. 2014;204:409\u201322.","journal-title":"J Cell Biol"},{"key":"3442_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev-biochem-061909-093311","volume":"82","author":"A Flotho","year":"2013","unstructured":"Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 2013;82:357\u201385.","journal-title":"Annu Rev Biochem"},{"key":"3442_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.trecan.2020.11.009","volume":"7","author":"JS Kroonen","year":"2021","unstructured":"Kroonen JS, Vertegaal AC. Targeting SUMO signaling to wrestle cancer. Trends Cancer. 2021;7:496\u2013510.","journal-title":"Trends Cancer"},{"key":"3442_CR15","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1159\/000488174","volume":"45","author":"Q Chen","year":"2018","unstructured":"Chen Q, Deng R, Zhao X, Yuan H, Zhang H, Dou J, et al. Sumoylation of EphB1 suppresses neuroblastoma tumourigenesis via inhibiting PKC\u03b3 activation. Cell Physiol Biochem. 2018;45:2283\u201392.","journal-title":"Cell Physiol Biochem"},{"key":"3442_CR16","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1021\/acs.biochem.5b00640","volume":"54","author":"S Packham","year":"2015","unstructured":"Packham S, Lin Y, Zha Z, Warsito D, Rutishouser D, Larsson O. The nucleus-localized epidermal growth factor receptor is SUMOylated. Biochemistry. 2015;54:5157\u201366.","journal-title":"Biochemistry"},{"key":"3442_CR17","first-page":"ra10","volume":"108","author":"B Sehat","year":"2010","unstructured":"Sehat B, Tofigh A, Lin Y, Trocm\u00e9 E, Liljedahl U, Lagergren J, et al. SUMOylation mediates the nuclear translocation and signalling of the IGF-1 receptor. Sci Signal. 2010;108:ra10.","journal-title":"Sci Signal"},{"key":"3442_CR18","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/onc.2014.165","volume":"34","author":"S Packham","year":"2015","unstructured":"Packham S, Warsito D, Lin Y, Sadi S, Karlsson R, Sehat B, et al. Nuclear translocation of IGF-1R via p150Glued and an importin-\u03b2\/RanBP2-dependent pathway in cancer cells. Oncogene. 2015;34:2227\u201338.","journal-title":"Oncogene"},{"key":"3442_CR19","doi-asserted-by":"publisher","first-page":"23216","DOI":"10.1074\/jbc.M111.335927","volume":"287","author":"M Sundvall","year":"2012","unstructured":"Sundvall M, Korhonen A, Vaparanta K, Anckar J, Halkilahti K, Salah Z, et al. Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem. 2012;287:23216\u201326.","journal-title":"J Biol Chem"},{"key":"3442_CR20","doi-asserted-by":"publisher","first-page":"19890","DOI":"10.1074\/jbc.M117.794271","volume":"292","author":"AM Knittle","year":"2017","unstructured":"Knittle AM, Helkkula M, Johnson MS, Sundvall M, Elenius K. SUMOylation regulates nuclear accumulation and signalling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase. J Biol Chem. 2017;292:19890\u2013904.","journal-title":"J Biol Chem"},{"key":"3442_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12860-023-00481-6","volume":"24","author":"K Wang","year":"2023","unstructured":"Wang K, Papadopoulos N, Hamidi A, Lennartsson J, Heldin CH. SUMOylation of PDGF receptor \u03b1 affects signalling via PLC\u03b3 and STAT3, and cell proliferation. BMC Mol Cell Biol. 2023;24:19.","journal-title":"BMC Mol Cell Biol"},{"key":"3442_CR22","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3390\/ijms24032544","volume":"24","author":"Q He","year":"2023","unstructured":"He Q, Chen Z, Li J, Liu J, Zuo Z, Lin B, et al. SENP6-mediated deSUMOylation of VEGFR2 enhances its cell membrane transport in angiogenesis. Int J Mol Sci. 2023;24:2544.","journal-title":"Int J Mol Sci"},{"key":"3442_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/CAD.0000000000000896","volume":"31","author":"M Wang","year":"2020","unstructured":"Wang M, Jiang X. SUMOylation of vascular endothelial growth factor receptor 2 inhibits the proliferation, migration, and angiogenesis signalling pathway in non-small cell lung cancer. Anti-Cancer Drugs. 2020;31:492\u20139.","journal-title":"Anti-Cancer Drugs"},{"key":"3442_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202631119","volume":"119","author":"X Zhu","year":"2022","unstructured":"Zhu X, Qiu C, Wang Y, Jiang Y, Chen Y, Fan L, et al. FGFR1 SUMOylation coordinates endothelial angiogenic signalling in angiogenesis. Proc Natl Acad Sci USA. 2022;119:e2202631119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3442_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.yexcr.2015.02.015","volume":"333","author":"I Mertens-Walker","year":"2015","unstructured":"Mertens-Walker I, Lisle JE, Nyberg WA, Stephens CR, Burke L, Rutkowski R, et al. EphB4 localises to the nucleus of prostate cancer cells. Exp Cell Res. 2015;333:105\u201315.","journal-title":"Exp Cell Res"},{"key":"3442_CR26","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.18632\/oncotarget.3199","volume":"6","author":"SA Stephenson","year":"2015","unstructured":"Stephenson SA, Douglas EL, Mertens-Walker I, Lisle JE, Maharaj MS, Herington AC. Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4. Oncotarget. 2015;6:7554.","journal-title":"Oncotarget"},{"key":"3442_CR27","doi-asserted-by":"publisher","first-page":"31043","DOI":"10.1074\/jbc.C300112200","volume":"278","author":"X Lin","year":"2003","unstructured":"Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH. SUMO-1\/Ubc9 promotes nuclear accumulation and metabolic stability of tumour suppressor Smad4. J Biol Chem. 2003;278:31043\u20138.","journal-title":"J Biol Chem"},{"key":"3442_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/EBC20253043","volume":"69","author":"JS Bhachoo","year":"2025","unstructured":"Bhachoo JS, Garvin AJ. DNA double strand break repair: a model of specificity and complexity in SUMO signalling. Essays Biochem. 2025;69:361\u201378.","journal-title":"Essays Biochem"},{"key":"3442_CR29","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","volume":"64","author":"SP Langston","year":"2021","unstructured":"Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, et al. Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer. J Med Chem. 2021;64:2501\u201320.","journal-title":"J Med Chem"},{"key":"3442_CR30","doi-asserted-by":"crossref","unstructured":"Dudek A, Juric D, Dowlati A, Vaishampayan U, Assad H, Rod\u00f3n J, et al. First-in-human Phase 1\/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumours or relapsed\/refractory lymphoma: Phase 1 results. J Immunother Cancer, 9 (abstract 476) (2021).","DOI":"10.1136\/jitc-2021-SITC2021.476"},{"key":"3442_CR31","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S0959-8049(22)01134-0","volume":"174","author":"G Saggu","year":"2022","unstructured":"Saggu G, Stroopinsky D, Dudek AZ, Olszanski AJ, Juric D, Dowlati A, et al. Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a Phase 1\/2 clinical study. Eur J Cancer. 2022;174:S125\u20136.","journal-title":"Eur J Cancer"},{"key":"3442_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1083\/jcb.140.3.499","volume":"140","author":"MJ Matunis","year":"1998","unstructured":"Matunis MJ, Wu J, Blobel G. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex. J Cell Biol. 1998;140:499\u2013509.","journal-title":"J Cell Biol"},{"key":"3442_CR33","doi-asserted-by":"publisher","first-page":"21664","DOI":"10.1074\/jbc.M100006200","volume":"276","author":"DA Sampson","year":"2001","unstructured":"Sampson DA, Wang M, Matunis MJ. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem. 2001;276:21664\u20139.","journal-title":"J Biol Chem"},{"key":"3442_CR34","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.celrep.2017.10.085","volume":"21","author":"D Wen","year":"2017","unstructured":"Wen D, Wu J, Wang L, Fu Z. SUMOylation promotes nuclear import and stabilization of polo-like kinase 1 to support its mitotic function. Cell Rep. 2017;21:2147\u201359.","journal-title":"Cell Rep"},{"key":"3442_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2005.03.012","volume":"18","author":"RT Hay","year":"2005","unstructured":"Hay RT. SUMO: a history of modification. Mol Cell. 2005;18:1\u201312.","journal-title":"Mol Cell"},{"key":"3442_CR36","doi-asserted-by":"publisher","first-page":"12654","DOI":"10.1074\/jbc.M009476200","volume":"276","author":"MS Rodriguez","year":"2001","unstructured":"Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem. 2001;276:12654\u20139.","journal-title":"J Biol Chem"},{"key":"3442_CR37","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41467-018-04957-4","volume":"9","author":"IA Hendriks","year":"2018","unstructured":"Hendriks IA, Lyon D, Su D, Skotte NH, Daniel JA, Jensen LJ, et al. Site-specific characterization of endogenous SUMOylation across species and organs. Nat Commun. 2018;9:2456.","journal-title":"Nat Commun"},{"key":"3442_CR38","doi-asserted-by":"publisher","first-page":"W238","DOI":"10.1093\/nar\/gkae346","volume":"52","author":"Y Gou","year":"2024","unstructured":"Gou Y, Liu D, Chen M, Wei Y, Huang X, Han C, et al. GPS-SUMO 2.0: an updated online service for the prediction of SUMOylation sites and SUMO-interacting motifs. Nucleic Acids Res. 2024;52:W238\u201347.","journal-title":"Nucleic Acids Res"},{"key":"3442_CR39","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1093\/bioinformatics\/btv403","volume":"31","author":"G Beauclair","year":"2015","unstructured":"Beauclair G, Bridier-Nahmias A, Zagury JF, Sa\u00efb A, Zamborlini A. JASSA: a comprehensive tool for prediction of SUMOylation sites and SIMs. Bioinformatics. 2015;31:3483\u201391.","journal-title":"Bioinformatics"},{"key":"3442_CR40","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/life13112153","volume":"13","author":"S Khan","year":"2023","unstructured":"Khan S, Khan M, Iqbal N, Dilshad N, Almufareh MF, Alsubaie N. Enhancing sumoylation site prediction: A deep neural network with discriminative features. Life. 2023;13:2153.","journal-title":"Life"},{"key":"3442_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/ncb1717","volume":"10","author":"V Lallemand-Breitenbach","year":"2008","unstructured":"Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. senic degrades PML or PML\u2013RAR\u03b1 through a SUMO-triggered RNF4\/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10:547\u201355.","journal-title":"Nat Cell Biol"},{"key":"3442_CR42","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1016\/j.febslet.2008.08.008","volume":"582","author":"SR Weisshaar","year":"2008","unstructured":"Weisshaar SR, Keusekotten K, Krause A, Horst C, Springer HM, G\u00f6ttsche K, et al. Arsenic trioxide stimulates SUMO-2\/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett. 2008;582:3174\u20138.","journal-title":"FEBS Lett"},{"key":"3442_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1074\/mcp.M700173-MCP200","volume":"7","author":"I Matic","year":"2008","unstructured":"Matic I, van Hagen M, Schimmel J, Macek B, Ogg SC, Tatham MH, et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol Cell Prot. 2008;7:132\u201344.","journal-title":"Mol Cell Prot"},{"key":"3442_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cells13010008","volume":"13","author":"W Wang","year":"2023","unstructured":"Wang W, Matunis MJ. 2023. Paralogue-specific roles of SUMO1 and SUMO2\/3 in protein quality control and associated diseases. Cells. 2023;13:8.","journal-title":"Cells"},{"key":"3442_CR45","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1091\/mbc.E21-01-0031","volume":"32","author":"D Bouchard","year":"2021","unstructured":"Bouchard D, Wang W, Yang WC, He S, Garcia A, Matunis MJ. SUMO paralogue\u2013specific functions revealed through systematic analysis of human knockout cell lines and gene expression data. Mol Biol Cell. 2021;32:1849\u201366.","journal-title":"Mol Biol Cell"},{"key":"3442_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1091\/mbc.E18-04-0252","volume":"30","author":"X Gong","year":"2019","unstructured":"Gong X, Liao Y, Ahner A, Larsen MB, Wang X, Bertrand CA, et al. Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation. Mol Biol Cell. 2019;30:4\u201316.","journal-title":"Mol Biol Cell"},{"key":"3442_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93933-y","volume":"11","author":"LC Chen","year":"2021","unstructured":"Chen LC, Hsieh YL, Tan GY, Kuo TY, Chou YC, Hsu PH, et al. Differential effects of SUMO1 and SUMO2 on circadian protein PER2 stability and function. Sci Rep. 2021;11:14431.","journal-title":"Sci Rep"},{"key":"3442_CR48","doi-asserted-by":"publisher","first-page":"42288","DOI":"10.18632\/oncotarget.9785","volume":"7","author":"D Warsito","year":"2016","unstructured":"Warsito D, Lin Y, Gnirck AC, Sehat B, Larsson O. Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein. Oncotarget. 2016;7:42288\u2013302.","journal-title":"Oncotarget"},{"key":"3442_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-21031-7","volume":"8","author":"R Titone","year":"2018","unstructured":"Titone R, Zhu M, Robertson DM. Insulin mediates de novo nuclear accumulation of the IGF-1\/insulin Hybrid Receptor in corneal epithelial cells. Sci Rep. 2018;8:1\u201313.","journal-title":"Sci Rep"},{"key":"3442_CR50","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.3390\/ijms23073639","volume":"23","author":"X Shi","year":"2022","unstructured":"Shi X, Du Y, Li S, Wu H. The role of SUMO E3 ligases in signalling pathway of cancer cells. Int J Mol Sci. 2022;23:3639.","journal-title":"Int J Mol Sci"},{"key":"3442_CR51","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.3390\/ijms23063281","volume":"23","author":"D Salas-Lloret","year":"2022","unstructured":"Salas-Lloret D, Gonz\u00e1lez-Prieto R. Insights in post-translational modifications: ubiquitin and SUMO. Int J Mol Sci. 2022;23:3281.","journal-title":"Int J Mol Sci"},{"key":"3442_CR52","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1038\/s41388-019-0931-2","volume":"38","author":"LY Liang","year":"2019","unstructured":"Liang LY, Patel O, Janes PW, Murphy JM, Lucet IS. Eph receptor signalling: from catalytic to non-catalytic functions. Oncogene. 2019;38:6567\u201384.","journal-title":"Oncogene"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03442-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03442-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03442-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:03:02Z","timestamp":1781546582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03442-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,5]]}},"alternative-id":["3442"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03442-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare competing financial interests; SS, WM and MSNM are the founding team of Kimaritec Pty Ltd. All other authors have no known competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were also performed in accordance with relevant guidelines and regulations and approved by Queensland University of Technology (approval number LR 2025-7021-25001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}